Insulin Glulisine: Preclinical Hallmarks and Clinical Effi Cacy
Total Page:16
File Type:pdf, Size:1020Kb
DRUG EVALUATION Insulin glulisine: preclinical hallmarks and clinical effi cacy Insulin glulisine (glulisine) is a new fast-acting human insulin analogue approved for treatment of diabetes Type 1 and 2. Preclinical investigations indicate mitogenic and metabolic potency similar to human insulin, but distinct β-cell protective properties, possibly related to a preferential effect on the insulin receptor substrate-2. Clinical trials with regular human insulin as a comparator consistently revealed superiority of glulisine with regard to glycemic control, which brought post-prandial glucose excursions closer to physiological levels without increasing the risk of hypoglycemia. Experimental trials showed specifi c advantages of glulisine in the treatment of obese and pediatric patients, which requires further evalulation. Certainly, glulisine represents a valuable tool for optimizing glycemic control, and thereby for attenuating micro- and macro-vascular complications. † KEYWORDS: β-cells euglycemic clamp insulin analogues insulin-like growth Freimut Schliess & factor proliferation obesity systems biology zinc Tim Heise †Author for correspondence: Insulin: physiological action & and two transmembrane β-subunits. Insulin Profi l Ins tut für signaling mechanisms binding triggers autophosphorylation of the Stoff wechselforschung GmbH, Metabolism & gene expression IR-β subunit, which allows recruitment and Hellersbergstrasse 9, D-41460 Insulin shifts cellular metabolism towards an tyrosine phosphorylation of insulin receptor Neuss, Germany anabolic state and is crucial for the systemic substrates (IRS), including IRS-1, IRS-2 and Tel.: +49 2131 4018 225; control of carbohydrate metabolism (FIGURE 1) [1] . the Src homology and collagen protein (Shc). Fax: +49 2131 4018 500; Insulin increases cellular glucose and amino IRS serve as interfaces between the insulin freimut.schliess@ acid uptake, glycolysis and glucose oxidation, as receptor and various signaling pathways lead- profi l-research.de well as the synthesis of glycogen, proteins, fatty ing, for instance, to the activation of PI 3-kinase acids and triglycerides. Simultaneously, insulin and protein kinase B (PKB) and mitogen- inhibits catabolic pathways such as gluco neo- activated protein (MAP) kinases such as the genesis and glycogenolysis, as well as lipolysis and extra cellular signal-regulated kinases Erk-1 and autophagic proteolysis. Insulin stimulates DNA -2 [12] . Cellular internalization of the insulin/IR synthesis and cell proliferation and protects cells complex leads to the degradation of insulin ini- from apoptosis – for instance in the setting of tiated by the insulin-degrading enzyme, which liver regeneration [2]. By preventing postprandial may contribute to the termination of insulin excursions of blood glucose, oxidative stress and signaling [13] . On the other hand, intracellular infl ammatory cytokines, insulin provides protec- insulin/IR complexes may even play an active tion from endothelial dysfunction and vascular part in signal transduction [14] . disease [3,4]. Insulin promotes complex changes As revealed by knockout experiments, insulin- in gene-expression patterns [5,6]. Recent investi- sensitive signal transduction pathways show a gations suggest that insulin action in the brain high degree of redundancy. For example, genetic may signifi cantly contribute to the regulation of deletion of IRS-1 led to the identifi cation of peripheral glucose and fat metabolism and, in IRS-1-independent signaling via IRS-2 [15–17] . concert with leptin, to hunger and satiety [7,8]. Furthermore, the insulin-sensitive signaling Metabolic insulin effects are antagonized by pathway is also addressed by other factors such glucagon, catecholamines and glucocorticoids. as insulin-like growth factor (IGF-1), with func- tional consequences different from those of insu- Signal transduction lin. Insulin and IGF-1 signals cross-talk with A complex signaling network activated by insu- each other by low-affi nity binding of insulin to lin binding to its plasma membrane receptor the IGF-1R, and IGF-1 to the IR, respectively, determines the exact insulin effect [9–11] (FIGURE 1). and the engagement of IR/IGF-1R hybrid recep- The insulin receptor (IR) is a receptor tyrosine tors [18,19] . Among others, the specifi c outcome kinase comprising two extracellular α-subunits of insulin signaling may critically depend on the 10.2217/14750708.6.2.209 © 2009 Future Medicine Ltd Therapy (2009) 6(2), 209–229 ISSN 1475-0708 209 DRUG EVALUATION Schliess & Heise expression profi le of cell surface receptors and prevents postprandial hyperglycemia, while a downstream operating signaling components, low basal insulin secretion accounts for normo- the cross-talk between signaling pathways and glycemia in the post-absorptive state [1,20,21] . the spatio–temporal compartmentalization of Insulin therapy of Type 1 diabetic patients signaling modules within the cellular matrix. is instituted at the time of diagnosis, and basal-bolus subcutaneous injection regimens Insulin therapy in people or continuous subcutaneous insulin infusion with diabetes (CSII) aim at mimicking meal-related and basal In healthy individuals, nutrient intake provokes a insulin secretion, which is widely absent in this biphasic insulin secretion by the pancreatic β-cells, clinical setting. In Type 2 diabetes, which is with maximum blood insulin concentrations characterized by insulin resistance and pro- achieved within 0.5–1 h, and a return to basal gressive loss of β-cell function, insulin is often levels within another 2–3 h. The meal-related administrated on top of an existing treatment endogenous insulin production almost perfectly with oral anti diabetic drugs (OADs) at later Insulin, IGF-1, insulin analogues PI3,4(P2) PI4(P) P-Tyr Tyr-P P-Tyr p110 p85 IRS-1/2 Tyr-P P-Tyr Tyr-P SHC PDK1 SHP-2 Grb2 Ptdins-3-kinase Grb2 PKB PKCλ PKCζ GLUT4 vesicles β PKB SOS SOS Ras Leu Raf-1 mTOR GSK3 Foxo MEK MAPK MNK1 pp1G p90rsk 4E-BP1 p70S6K eIF-4E MKP + Glucose uptake Metabolic effects + Amino acid uptake + Glycogen synthesis + Protein synthesis + Glycolysis - Proteolysis - Gluconeogenesis + Fatty acid synthesis + DNA synthesis + Triglyceride synthesis + Proliferation - Lipid degradation - Apoptosis Figure 1. Signaling pathways responsive to insulin, insulin analogues and IGF-1. The scheme depicts part of the cellular signaling network responsive to insulin, IGF-1 and insulin analogues. Insulin and IGF-1 bind with high affi nity to their cognate receptors, and thereby induce distinct, cell-type- and environment-specifi c signaling patterns. In addition, there is low-affi nity binding of insulin (analogues) to the IGF-1 receptor (IGF1-R), and of IGF-1 to the insulin receptor (IR), respectively, and the activation of IR/IGF-1R hybrids induced by ligand binding, autophosphorylation of receptor tyrosine residues generates docking sites for insulin receptor substrates (such as IRS-1, IRS-2 and Shc), which feed signals in different areas of the network. Although signaling pathways can be identifi ed (e.g., the Ras–Raf–MEK–MAPK pathway, the PI 3-kinase–PKB pathway or the intracellular amino acid-dependent signaling via the mammalian target of rapamycin [mTOR]) it should be noted that the activation of specifi c patterns rather than linear pathways mediates the entire metabolic response to insulin, insulin analogues and IGF-1. Further information is provided in the text and in [9–14]. Adapted from [10]. 210 Therapy (2009) 6(2) future science group Insulin glulisine: preclinical hallmarks & clinical effi cacy DRUG EVALUATION stages of the disease, with a stepwise intensi- ability of hexameric insulin to dissociate into fi cation of insulin therapy over the following dimers and monomers that can readily permeate years [22,23]. the capillary wall [20,25,27]. At a concentration of approximately 10–3 mol/l in commercially avail- The design of fast-acting able human insulin preparations, approximately insulin analogues 75% of the insulin molecules assemble to the hex- Subcutaneous insulin injections poorly mimic amer formation via trimerization of dimers [26]. the physiological pattern of endogenous meal- Dilution of insulin solutions promotes disso- related and basal insulin secretion. Endogenous, ciation of the hexameric insulin, and the initial but not subcutaneously administrated insulin lag phase of insulin absorption refl ects the time fi rst passes the liver, which is pivotal for estab- required for suffi cient dilution of subcutaneously lishment of the portal–peripheral insulin gra- deposited insulin hexamers around Zn2+, which dient and adequate postprandial glucose con- makes dimeric and monomeric insulin available trol [24]. Furthermore, absorption of regular for absorption. human insulin (RHI) from a subcutaneous Fast-acting human insulin analogues were depot into the circulation is delayed by a lag designed with the objective to provide insu- phase of approximately 3–4 h, which accounts lin-related drugs that are absorbed faster than for a mismatch between the postprandial rise RHI, but at the same time ideally match the of blood glucose concentration and the avail- properties of human insulin regarding recep- ability of insulin. This increases the incidence tor binding, post-receptor signaling, mitogenic of both post-prandial hyperglycemia and late potency and glucodynamic effi cacy. Based on post-absorptive hypoglycemia [20,25]. As Robert x-ray crystallographic investigations and studies Tattersall noted years ago, insulin is given in with mutagenated